<DOC>
	<DOC>NCT00396071</DOC>
	<brief_summary>This mechanistic study will evaluate the effect of vildagliptin on glucose-stimulated insulin secretion to improve the incretin effect in patients with type 2 diabetes.</brief_summary>
	<brief_title>Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Incretins</mesh_term>
	<criteria>Patients with type 2 diabetes on metformin for at least 3 months and have been on a stable dose of at least 1500 mg daily for a minimum of 4 weeks Agreement to maintain the same dose of metformin throughout the study Body mass index (BMI) in the range of 2235 kg/m2 HbA1c in the range of 7.0 to 9.0% FPG &lt;200 mg/dl (11.1 mmol/L) Agreement to maintain prior diet and exercise habits during the full course of the study Ability to comply with all study requirements and signed informed consent to participate in the study A history of type 1 diabetes A history of acute metabolic diabetic complications Evidence of significant diabetic complications Insulin treatment for longer than 10 days within the past 6 months Treatment with any oral antidiabetic other than metformin within 3 months prior to visit 1 Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>incretin effect</keyword>
	<keyword>metformin</keyword>
</DOC>